US 12,138,281 B2
Methods of treating chronic inflammatory diseases
Chong-Hwan Chang, Incheon (KR); and Keun-Yeong Jeong, Seoul (KR)
Assigned to METIMEDI PHARMACEUTICALS CO., LTD., Uiwang-si (KR)
Filed by METIMEDI PHARMACEUTICALS CO., LTD., Uiwang-si (KR)
Filed on May 9, 2023, as Appl. No. 18/314,442.
Application 18/314,442 is a continuation of application No. 17/131,820, filed on Dec. 23, 2020, granted, now 11,684,635.
Application 17/131,820 is a continuation of application No. 16/942,757, filed on Jul. 29, 2020, granted, now 10,898,514, issued on Jan. 6, 2021.
Application 16/942,757 is a continuation of application No. 16/246,252, filed on Jan. 11, 2019, granted, now 10,751,365, issued on Aug. 25, 2020.
Claims priority of provisional application 62/616,923, filed on Jan. 12, 2018.
Prior Publication US 2023/0302046 A1, Sep. 28, 2023
Int. Cl. A61K 33/06 (2006.01); A61K 9/00 (2006.01); A61K 31/19 (2006.01); A61K 47/36 (2006.01); A61P 1/16 (2006.01); A61P 9/10 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01)
CPC A61K 33/06 (2013.01) [A61K 9/00 (2013.01); A61K 31/19 (2013.01); A61K 47/36 (2013.01); A61P 1/16 (2018.01); A61P 9/10 (2018.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01)] 9 Claims
 
1. A method of treating fibrosis comprising:
administering to a subject in need thereof a pharmaceutical composition comprising:
a therapeutically effective amount of calcium lactate;
a polymer; and
a lipid,
wherein,
the weight ratio of the polymer to the lipid is 1:0.1 to 1:50,
wherein the weight ration of the calcium lactate to the polymer and/or lipid is at least 1.5.